Clinics in Dermatology
Volume 26, Issue 5 , Pages 438-447 , September 2008

Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine

References 

  1. Farber S. Temporary remission of acute leukaemia in children produced by the folic acid antagonist 4 aminopteroylglutamic acid (aminopterin). N Engl J Med. 1948;238:787
  2. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci. 1951;221:176–182
  3. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm. 1958;78:200–203
  4. Matherly LH. In: Distribution of the reduced folate carrier (RFC) versus the high affinity membrane folate binding protein (mFBP) in human tumours and tissues. 35 ed.. 1994;p. 307–315
  5. Schlemmer SR, Sirotnak FM. Retentiveness of methotrexate polyglutamates in cultured L1210 cells. Evidence against a role for mediated plasma membrane transport outward. Biochem Pharmacol. 1993;45:1261–1266
  6. McGuire JJ. In: Pteroylpolyglutamates: biosynthesis, degradation, and function. New York: John Wiley; 1984;p. 135–190
  7. Chu E. In: Cancer chemotherapy and biotherapy. Philadelphia: Lippincot-Raven; 1996;p. 109–147
  8. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum. 1998;27:277–292
  9. Szeto DW, Cheng YC, Rosowsky A, et al. Human thymidylate synthetase—III. Effects of methotrexate and folate analogs. Biochem Pharmacol. 1979;28:2633–2637
  10. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest. 1985;76:907–912
  11. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res. 2002;4:266–273
  12. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675–2682
  13. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986;236:193–200
  14. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985;82:4881–4885
  15. Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992;148:2201–2206
  16. Sperling RI, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME. Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992;35:376–384
  17. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322–328
  18. Mirabet M, Herrera C, Cordero OJ, Mallol J, Lluis C, Franco R. Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci. 1999;112(Pt 4):491–502
  19. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114:154–163
  20. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol. 1971;103:33–38
  21. Weinstein GD, Goldfaden G, Frost P. Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol. 1971;104:236–243
  22. Black RL, O'Brien WM, Vanscott EJ, Uerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA. 1964;189:743–747
  23. Nyfors A, Brodthagen H. Methotrexate for psoriasis in weekly oral doses without any adjunctive therapy. Dermatologica. 1970;140:345–355
  24. Jeffes EW, Weinstein GD. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin. 1995;13:875–890
  25. Van de Kerkhof PC, Mali JW. Methotrexate maintenance following Ingram therapy in ‘difficult’ psoriasis. Br J Dermatol. 1982;106:623–627
  26. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med. 2003;349:658–665
  27. Collins P, Rogers S. The efficacy of methotrexate in psoriasis—a review of 40 cases. Clin Exp Dermatol. 1992;17:257–260
  28. Baker H. In: Methotrexate: the conservative treatment for psoriasis. York Medical Books; 1976;p. 235–245
  29. Zachariae H, Zachariae E. Methotrexate treatment of psoriatic arthritis. Acta Derm Venereol. 1987;67:270–273
  30. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull. 1978;25:208–211
  31. Fairris GM, Dewhurst AG, White JE, Campbell MJ. Methotrexate dosage in patients aged over 50 with psoriasis. BMJ. 1989;298:801–802
  32. Baker H. Some hazards of methotrexate treatment of psoriasis. Trans St Johns Hosp Dermatol Soc. 1970;56:111–116
  33. Morison WL, Momtaz K, Parrish JA, Fitzpatrick TB. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982;6:46–51
  34. Paul BS, Momtaz K, Stern RS, Arndt KA, Parrish JA. Combined methotrexate-ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982;7:758–762
  35. Armstrong RB, Poh-Fitzpatrick MB. Methotrexate and ultraviolet radiation. Arch Dermatol. 1982;118:177–178
  36. Vanderveen EE, Ellis CN, Campbell JP, Case PC, Voorhees JJ. Methotrexate and etretinate as concurrent therapies in severe psoriasis. Arch Dermatol. 1982;118:660–662
  37. Fitzsimons CP, Long J, MacKie RM. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. Lancet. 1983;1:235–236
  38. Gollnick HP. Oral retinoids—efficacy and toxicity in psoriasis. Br J Dermatol. 1996;135(Suppl 49):6–17
  39. Horiguchi M, Takigawa M, Imamura S. Treatment of generalized pustular psoriasis with methotrexate and colchicine. Arch Dermatol. 1981;117:760
  40. Clark CM, Kirby B, Morris AD, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141:279–282
  41. Aydin F, Canturk T, Senturk N, Turanli AY. Methotrexate and cyclosporine combination for the treatment of severe psoriasis. Clin Exp Dermatol. 2006;31:520–524
  42. Salim A, Tan E, Ilchyshyn A, Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2006;154:1169–1174
  43. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53:652–659
  44. Roenigk HH, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145–156
  45. Kaplan DL, Olsen EA. Erosion of psoriatic plaques after chronic methotrexate administration. Int J Dermatol. 1988;27:59–62
  46. Baker H. Intermittent high dose oral methotrexate therapy in psoriasis. Br J Dermatol. 1970;82:65–69
  47. Smith JD, Knox JM. Psoriasis, methotrexate and tuberculosis. Br J Dermatol. 1971;84:590–593
  48. Roenigk HH, Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol. 1998;38:478–485
  49. Zachariae H, Sogaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venereol. 1989;69:241–244
  50. Boffa MJ, Smith A, Chalmers RJ, et al. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol. 1996;135:538–544
  51. Zachariae H, Heickendorff L, Sogaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol. 2001;144:100–103
  52. Zonneveld IM, Bakker WK, Dijkstra PF, Bos JD, van Soesbergen RM, Dinant HJ. Methotrexate osteopathy in long-term, low-dose methotrexate treatment for psoriasis and rheumatoid arthritis. Arch Dermatol. 1996;132:184–187
  53. Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol. 1980;116:215–217
  54. Jensen DB, Albrektsen SB, Krag C. Development of metastatic skin cancer during methotrexate therapy for psoriasis. Acta Derm Venereol. 1989;69:274–275
  55. Stern RS, Laird N. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer. 1994;73:2759–2764
  56. Warren RB, Griffiths CE. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol. 2005;153:869–873
  57. King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982;107:583–590
  58. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther. 2006;9:264–271
  59. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38:705–711
  60. Wiegand UW, Chou RC. Pharmacokinetics of acitretin and etretinate. J Am Acad Dermatol. 1998;39:S25–S33
  61. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol. 1993;100:623–627
  62. Saurat JH, Hirschel-Scholz S, Salomon D, Siegenthaler G. Human skin retinoid-binding proteins and therapy with synthetic retinoids: a still unexplained link. Dermatologica. 1987;175(Suppl 1):13–19
  63. Brand N, Petkovich M, Krust A, et al. Identification of a second human retinoic acid receptor. Nature. 1988;332:850–853
  64. Chandraratna RA. Tazarotene—first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135(Suppl 49):18–25
  65. Harper RA. Specificity in the synergism between retinoic acid and EGF on the growth of adult human skin fibroblasts. Exp Cell Res. 1988;178:254–263
  66. Detmar M, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180:1141–1146
  67. Diaz BV, Lenoir MC, Ladoux A, Frelin C, Demarchez M, Michel S. Regulation of vascular endothelial growth factor expression in human keratinocytes by retinoids. J Biol Chem. 2000;275:642–650
  68. Dupuy P, Bagot M, Heslan M, Dubertret L. Synthetic retinoids inhibit the antigen presenting properties of epidermal cells in vitro. J Invest Dermatol. 1989;93:455–459
  69. Bauer R, Schutz R, Orfanos CE. Impaired motility and random migration of vital polymorphonuclears in vitro after therapy with oral aromatic retinoid in psoriasis. Int J Dermatol. 1984;23:72–77
  70. Olsen EA, Weed WW, Meyer CJ, Cobo LM. A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. J Am Acad Dermatol. 1989;21:681–686
  71. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol. 1988;19:186–191
  72. Torok L, Kadar L, Geiger JM. Acitretin treatment of severe psoriasis. Acta Derm Venereol Suppl (Stockh). 1989;146:104–106
  73. Lassus A, Geiger JM, Nyblom M, Virrankoski T, Kaartamaa M, Ingervo L. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol. 1987;117:333–341
  74. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica. 1988;176:182–190
  75. Goldfarb MT, Ellis CN, Gupta AK, Tincoff T, Hamilton TA, Voorhees JJ. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol. 1988;18:655–662
  76. Van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther. 2006;9:252–263
  77. Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001;45:544–553
  78. Van de Kerkhof PC, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 micrograms/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138:84–89
  79. Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin. 2004;22:467–476
  80. Ling MR. Acitretin: optimal dosing strategies. J Am Acad Dermatol. 1999;41:S13–S17
  81. Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol. 1988;19:458–468
  82. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1–125
  83. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991;25:682–684
  84. Saurat JH, Geiger JM, Amblard P, et al. Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis. Dermatologica. 1988;177:218–224
  85. Ruzicka T, Sommerburg C, Braun-Falco O, et al. Efficiency of acitretin in combination with UV-B in the treatment of severe psoriasis. Arch Dermatol. 1990;126:482–486
  86. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991;24:591–594
  87. Bavinck JN, Tieben LM, Van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13:1933–1938
  88. Fisher GJ, Talwar HS, Lin J, et al. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest. 1998;101:1432–1440
  89. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–841
  90. Roenigk HH, Callen JP, Guzzo CA, et al. Effects of acitretin on the liver. J Am Acad Dermatol. 1999;41:584–588
  91. Kilcoyne RF. Effects of retinoids in bone. J Am Acad Dermatol. 1988;19:212–216
  92. Mahrle G, Meyer-Hamme S, Ippen H. Oral treatment of keratinizing disorders of skin and mucous membranes with etretinate. Comparative study of 113 patients. Arch Dermatol. 1982;118:97–100
  93. Griffiths CE, Dabelsteen E, Voorhees JJ. Topical retinoic acid changes the epidermal cell surface glycosylation pattern towards that of a mucosal epithelium. Br J Dermatol. 1996;134:431–436
  94. Wanner R, Wolff B, Glowacki F, Kolde G, Wittig B. The loss of desmosomes after retinoic acid treatment results in an apparent inhibition of HaCaT keratinocyte differentiation. Arch Dermatol Res. 1999;291:346–353
  95. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6:468–475
  96. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13:136–142
  97. Clipstone NA, Crabtree CG. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature. 1992;357:695–697
  98. Al-Daraji WI, Grant KR, Ryan K, et al. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol. 2002;118:779–788
  99. Fisher GJ, Duell EA, Nickoloff BJ, et al. Levels of cyclosporin in epidermis of treated psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free versus serum containing media. J Invest Dermatol. 1998;91:142–146
  100. Mueller W, Hermann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301:555
  101. Griffiths CEM, Powles AV, Leonard JN, et al. Clearance of psoriasis with low dose cyclosporin. Br Med J. 1986;293:731–732
  102. Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110–3116
  103. Van Joost T, Bos JD, Heule F, et al. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol. 1988;118:183–190
  104. Griffiths CEM, Dubertret L, Ellis CN, et al. cyclosporine in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004;150:11–23
  105. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systemic review of treatments for severe psoriasis. Health Technol Assess. 2000;4:1–125
  106. Ellis CN, Fradin MS, Messana JM, et al. Cyclosporine for plaque-type psoriasis: results of a multi-dose, double-blind trial. N Engl J Med. 1991;324:277–284
  107.  Finzi AFCyclosporin in severe psoriasis: the Italian experience. Dermatology. 1993;187(Suppl 1):
  108. Berth-Jones J, Henderson CA, Munro CS, et al. Treatment of psoriasis with intermittent short-course cyclosporin (Neoral). A multicentre study. Br J Dermatol. 1997;136:527–530
  109. Ho VCY, Albrecht G, Vanaclocha F, et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol. 1999;141:283–291
  110. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol. 2001;44:643–651
  111. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporine in severe psoriasis: results of a meta-analysis. Am J Clin Dermatol. 2001;2:41–47
  112. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol. 1997;36:423–432
  113. Koo J for the OLP302 Study Group. A randomised, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol. 1998;139:88–95
  114. Powles AV, Baker BS, Valdimarsson H, et al. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol. 1990;36(suppl):13–19
  115. Mrowietz U, Faerber L, Henneicke-von Zepelin HH, et al. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol. 1995;33:470–475
  116. Mihatsch MJ, Wolff K. A consensus report: cyclosporin A therapy for psoriasis. Br J Dermatol. 1990;122:1–3
  117. Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases. N Engl J Med. 1992;326:1654–1660
  118. Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis treated with cyclosporine: a 5-yr cohort study. J Invest Dermatol. 2003;120:211–216
  119. Katz HI. Potential drug interactions with cyclosporine. Int J Dermatol. 1997;36:18–24
  120. Griffiths CEM, Katsambas A, Dijkmans BA, et al. Update on the use of cyclosporine in immune-mediated dermatoses. Br J Dermatol. 2006;155:1–26
  121. Ameen M, Smith HR, Barker JNWN. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin Exp Dermatol. 2001;26:480–483

☆ Conflict of interest statement: C.E.M.G. is a consultant to and has received research funding, travel grants, and lecture fees from Novartis.

PII: S0738-081X(07)00266-0

doi: 10.1016/j.clindermatol.2007.11.006

Clinics in Dermatology
Volume 26, Issue 5 , Pages 438-447 , September 2008

Article Tools

* Image Usage & Resolution